Literature DB >> 949243

Pancreatitis and severe metabolic abnormalities due to phenformin therapy.

G M Graeber, B M Marmor, R C Hendel, R O Gregg.   

Abstract

Two elderly diabetic patients with abdominal pain were demonstrated to have complications of phenformin hydrochloride therapy. The first developed severe lactic acidosis treated with sodium bicarbonate given intravenously and followed by rebound alkalosis. The second showed severe acidosis (specimens for lactate determination were unfortunately unsatisfactory for analysis) and similar alkalotic rebound after therapy. She then developed severe pancreatitis, proved at operation, no cause for which other than phenformin was apparent. Poor renal and hepatic function predispose to these conditions by increasing serum phenformin levels and by decreasing urinary excretion of its metabolites. The acidosis should be treated judiciously with sodium bicarbonate administered intravenously. A rebound alkalosis, ensuring as the accumulated lactate is metabolized, is best treated by potassium chloride and ammonium chloride given intravenously. The mechanism by which phenformin causes pancreatitis is unknown, but termination of therapy causes cessation of the pancreatitis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 949243     DOI: 10.1001/archsurg.1976.01360270086016

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Iatrogenic pancreatitis.

Authors: 
Journal:  Br Med J       Date:  1977-10-22

Review 2.  Drug-induced pancreatitis.

Authors:  T Wilmink; T W Frick
Journal:  Drug Saf       Date:  1996-06       Impact factor: 5.606

Review 3.  Lactic acidosis in biguanide-treated diabetics: a review of 330 cases.

Authors:  D Luft; R M Schmülling; M Eggstein
Journal:  Diabetologia       Date:  1978-02       Impact factor: 10.122

4.  Topical Inhibition of the Electron Transport Chain Can Stimulate the Hair Cycle.

Authors:  Matilde Miranda; Heather Christofk; D Leanne Jones; William E Lowry
Journal:  J Invest Dermatol       Date:  2017-10-26       Impact factor: 8.551

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.